In light of ALK-directed therapy, what is the role of chemotherapy for patients with newly diagnosed ALK+ DLBCL?

I haven’t seen any data on ALK inhibitors in DLBCL, I’m assuming partly since it’s a small subset of DLBCL. Presumably, toxicity would be similar to, say, a BTKi + R-CHOP? Maybe would consider off label in the R/R setting, but would not use upfront.

Those with ALK+ ALCL typically do well. In that sce...